PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 79.53

Change

0.00 (0.00)%

Market Cap

USD 4.13B

Volume

0.31M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 26.96B
PODD Insulet Corporation

N/A

USD 16.27B
BRKR Bruker Corporation

N/A

USD 10.70B
MASI Masimo Corporation

N/A

USD 7.12B
TMDX TransMedics Group Inc

N/A

USD 5.50B
AXNX Axonics Modulation Technologie..

N/A

USD 3.55B
QDEL Quidel Corporation

N/A

USD 3.06B
TNDM Tandem Diabetes Care Inc

N/A

USD 2.89B
LIVN LivaNova PLC

N/A

USD 2.85B
UFPT UFP Technologies Inc

N/A

USD 2.49B

ETFs Containing PRCT

W311:XETRA HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 89.76% 66% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.76% 66% D+ 80% B-
Trailing 12 Months  
Capital Gain 142.40% 68% D+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 142.40% 68% D+ 83% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 21.24% N/A N/A 79% B-
Dividend Return 21.24% N/A N/A 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.67% N/A N/A 41% F
Risk Adjusted Return 48.65% N/A N/A 78% C+
Market Capitalization 4.13B 95% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector